First Hawaiian Bank Lowers Holdings in Sanofi (NASDAQ:SNY)

First Hawaiian Bank lessened its stake in Sanofi (NASDAQ:SNY) by 9.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 118,415 shares of the company’s stock after selling 12,981 shares during the quarter. First Hawaiian Bank’s holdings in Sanofi were worth $5,745,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Venturi Wealth Management LLC increased its holdings in Sanofi by 163.5% in the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after buying an additional 332 shares in the last quarter. Frazier Financial Advisors LLC bought a new stake in Sanofi in the 4th quarter worth about $28,000. Larson Financial Group LLC increased its holdings in Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after buying an additional 500 shares in the last quarter. Register Financial Advisors LLC bought a new stake in shares of Sanofi during the 1st quarter valued at about $29,000. Finally, McIlrath & Eck LLC grew its stake in shares of Sanofi by 143.3% during the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock valued at $30,000 after purchasing an additional 361 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ SNY traded up $1.39 during midday trading on Friday, reaching $53.05. 2,499,226 shares of the stock traded hands, compared to its average volume of 2,379,002. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market capitalization of $134.36 billion, a PE ratio of 26.66, a P/E/G ratio of 1.50 and a beta of 0.59. Sanofi has a one year low of $42.63 and a one year high of $55.72. The company’s 50 day moving average is $49.51 and its 200 day moving average is $48.67.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s revenue was up 7.8% on a year-over-year basis. During the same period last year, the company earned $0.95 earnings per share. On average, equities research analysts anticipate that Sanofi will post 4.16 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SNY shares. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.